| Date | Title | Description |
| 10.09.2026 | PW Consulting: Global Sedative-Hypnotic Drug Market Hits $4.85B in 2025, Projected 5.85% CAGR to 2032 | Navigating the Global Sedative-Hypnotic Drug Market: Strategic Imperatives for 2026 and Beyond
The global healthcare landscape is undergoing a significant transformation, driven by an aging population, increasing prevalence of sleep disorde... |
| 24.07.2026 | Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges | U.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen... |
| 22.07.2026 | Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply | Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing.
But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details r... |
| 15.12.2025 | Hikma: FTSE 100 giant’s boss replaced by former chief after share price woes | The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year.
Riad Mishlawi has exited his role as chief executive at Hikma, with execut... |
| 21.10.2025 | SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform | SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization.
SEOUL, South Korea, Oct. 21, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a b... |
| 16.06.2025 | FTSE 100 shrugs off Israel-Iran strikes | The FTSE 100 was unmoved by simmering tensions in Israel and Iran, despite reports that the UK was scrambling to send fighter jets, and conflict in the Middle East was on the brink of a significant escalation with US involvement.
The UK’s l... |
| 27.04.2025 | Biolinq: $100 Million Series C Funding Raised For Advancing Biowearable Platform For Metabolic Health | Biolinq, a healthcare technology company pioneering precision multi-analyte biosensors to improve metabolic health, announced a $100 million Series C funding round led by Alpha Wave Ventures. Existing investors RiverVest Venture Partners, A... |
| 23.04.2025 | Biolinq's $100 Million Leap: A New Era for Diabetes Management | In the world of health technology, innovation is the lifeblood. Biolinq, a California-based company, has just injected a hefty $100 million into its vision for the future of diabetes management. This Series C funding round, led by Alpha Wav... |
| 22.04.2025 | Biolinq raises $100M for intradermal glucose sensor for type 2 diabetes | Photo courtesy of Biolinq
Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it secured $100 million in Series C funding.
Alpha Wave Ventures led the round with partic... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 20.03.2025 | Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg | LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Cana... |
| 20.03.2025 | Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg | Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (... |
| 26.02.2025 | Hikma’s profit jumps as demand for generic medicines booms | - |
| 09.10.2024 | The Connell Company Unveils Round Table Workspaces at The Park in Berkeley Heights, NJ | The Park, formerly known as Connell Corporate Park, is undergoing a $500 million repositioning to bring an urban energy and community to the suburbs. (Photo provided by The Connell Company)
1,500,000-square-feet of modernized and elevated w... |
| 03.09.2024 | General Anesthesia Drugs Market: Trends, Segmentation, and Future Outlook | Share
Tweet
Share
Share
Email
The global general anesthesia drugs market has been experiencing significant evolution, driven by advancements in medical technology, increasing surgical procedures, and a growing emphasis on patient safety and... |
| 02.05.2024 | Granules India receives USFDA approval for Colchicine capsules | Granules India has received an approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc. (GPI), a wholly owned foreign subsidiary of the company for Co... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 01.02.2024 | February 1, 2024 - Attorney General Miyares Announces $150M Multistate Settlement with Hikma Pharmaceuticals | Commonwealth of Virginia
Office of the Attorney General
Jason S. Miyares
Attorney General
202 North 9th Street
Richmond, Virginia 23219
804-786-2071
FAX 804-786-1991
Virginia Relay Service
800-828-1120
For media inquiries only, contact:
Vic... |
| 08.01.2024 | Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa | PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreemen... |
| 10.10.2023 | CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region | SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in the Middle East and North A... |
| 30.04.2022 | Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals | LONDON, April 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceu... |
| 25.04.2022 | Digital health news, funding roundup in the prior week; April 25, 2022 | Mount Sinai's new fund; DOJ appealed lifting of mask mandate; Amwell expanded to MSK and dermatology
Top Health News
Mount Sinai Innovation Partners (MSIP), the commercialization arm of the Mount Sinai Health System in New York, launched i3... |
| 07.04.2022 | Egypt’s O7 Therapy lands game-changing $2.1M in funding | Credit: O7 Therapy |
| 24.01.2022 | The National Children’s Cancer Society receives donations from Hikma to ensure delivery of lifesaving medicine to children battling cancer | “Hikma is proud to partner with The National Children’s Cancer Society and support their efforts to help children battling cancer,” said Kelly Benoit, Manager, Corporate Social Responsibility, Hikma.
ST. LOUIS (PRWEB) January 24, 2022
The N... |
| 10.01.2022 | Hikma Pharmaceuticals : 40th Annual JP Morgan Healthcare Conference Presentation | Better health.
Within reach.
Every day.
Hikma Pharmaceuticals PLC
JP Morgan Healthcare Conference January 2022
Disclaimer
Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other... |
| 27.09.2021 | Hikma Strengthens US Injectables Business through Acquisition of Custopharm | Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company and one of the largest suppliers of generic injectable medicines in the US, announces that it has agreed to acquire Custopharm Inc. (‘Custopharm’) from Water Street... |
| 04.08.2021 | Hikma announces US launch of KLOXXADO™ (naloxone HCl) nasal spray 8mg | |
| 09.06.2021 | Hikma appoints Patrick Genestin to lead Generics Business Development | |
| 28.04.2021 | AFT PHARMACEUTICALS LIMITED
GENERAL: AFT: AFT licenses Maxigesic® IV in the USOpens in a new Window | 28 April 2021
AFT licenses Maxigesic® IV in the US
Agreement with Hikma, the US' third largest supplier of generic injectable medications by volume1, will see AFT benefit from upfront, regulatory and commercial milestone payments worth up t... |
| 20.04.2021 | HIKMA PHARMACEUTICALS PLC
Hikma Pharmaceuticals : resumes launch of generic Advair Diskus® | LONDON, April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus®1 in the US following US ... |
| 18.02.2021 | Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer ... | |
| 17.12.2020 | Hikma launches generic Advair Diskus® following FDA approval | |
| 03.09.2020 | Hikma receives favourable court ruling for its generic Vascepa® | |
| 23.06.2020 | Boehringer Ingelheim to cash out Hikma stake; Breast cancer biotech sets terms for IPO | → Boehringer Ingelheim is offloading a major chunk of its holding in Hikma, proposing to sell 28 million out of 40 million shares of the London-listed drugmaker. The stake is valued at nearly £1 billion, and Hikma has com... |
| 05.05.2020 | Hikma Ventures invests in Altoida | The number of people living with Alzheimer's disease is rapidly growing. In 2019 alone, Alzheimer's disease and other dementias cost the US $290 billion. By 2050, these costs could rise as high as $1.1 trillion, according to the 2019 Facts ... |
| 05.05.2020 | Hikma Ventures invests in Altoida | |
| 31.03.2020 | Amarin’s shares sink as federal judge invalidates patent on cardiovascular drug | Shares of Amarin fell 67% following the ruling on the Nasdaq and were down more than 68% when markets opened Tuesday. Shares of Dr. Reddy’s and Hikma were up more than 4% on the National Stock Exchange of India and 2.7% on the London Stock ... |
| 09.08.2019 | FDA rejects Kala's dry eye drug; Troubled Insys finds a buyer (of some assets) in Hikma | → Kala Pharmaceuticals, one of the plethora of biotechs that trace their roots to the prolific lab at MIT led by Bob Langer, on Thursday disclosed that its experimental drug for short-term dry eye relief did not pass muster wi... |
| 23.02.2018 | Seeking greater gender diversity, Alnylam promotes four female leaders; Paul Hastings starts post-OncoMed career as CEO of stealthy Nkarta | Leila Jalinous
→ Consistent with a goal to foster gender diversity in its leadership ranks, Alnylam has promoted four female leaders to VP level. Kelly Bierly is now VP, commercial counsel, providing legal support ... |
| 30.11.2017 | Prognos Raises $20.5M For AI-Powered Disease Prediction Platform for Payers, Providers | Prognos, a New York City-based healthcare Artificial Intelligence (AI) startup that has been steadfastly building its AI capabilities with the goal of predicting disease has raised $20.5 million in Series C funding. Particpatnts in the roun... |
| 21.11.2013 | Hikma takes corporate reporting to the next level with CRedit360 sustainability software | Jordan’s leading pharmaceutical company, Hikma Pharmaceuticals, invested in CRedit360’s award-winning sustainability software to improve the quality of its corporate responsibility (CR) reporting and ultimately its sustainability performanc... |
| 21.11.2013 | Hikma takes corporate reporting to the next level with CRedit360 sustainability software | Hikma takes corporate reporting to the next level with CRedit360 sustainability software
21-11-2013
Jordan’s leading pharmaceutical company, Hikma Pharmaceuticals, invested in CRedit360’s award-winning sustainability software to improve the... |
| - | Amarin’s shares sink as federal judge invalidates patent on cardiovascular drug | A federal court in Nevada struck down the patent protection on a drug used to lower the risk of heart attacks, sending the manufacturer’s shares diving.
Las Vegas District Judge Miranda Du ruled Monday in favor of two generic companies that... |
